Abattis Bioceuticals Corp. (OTCPK:ATTB.F) entered into a non-binding letter of intent to acquire Winston Resources Inc. (CNSX:WRW) for CAD 12.2 million on December 22, 2017. As per the consideration, Abattis Bioceuticals Corp. will issue 25 million common shares in exchange of all of the issued and outstanding common shares of Winston Resources at the time of closing of the transaction. Post-acquisition, Winston Resources shareholders will own approximately 10.2% of Abattis Bioceuticals Corp.'s issued and outstanding common shares. In a related transaction, Abattis Bioceuticals Corp. entered into a non-binding letter of intent to acquire all of the issued and outstanding common shares of GT Therapeutics Corporation in exchange of 5.5 million Abattis shares. The letter of intent is expected to be superseded by a definitive agreement which will be subject to completion of due diligence, receipt of required consents and approvals including approval of Canadian Stock Exchange (CSE) and approval of shareholders of Winston Resources.

Abattis Bioceuticals Corp. (OTCPK:ATTB.F) cancelled the acquisition of Winston Resources Inc. (CNSX:WRW) on June 28, 2019.